Dierk Scheinert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dierk Scheinert has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Thomas Zeller
Department of Interventional Angiology, University Hospital Freiburg/Bad Krozingen, Bad Krozingen, Germany
4 shared publications - Thomas Lehmann
Institute for Medical Statistics, Computer Science and Data Science, Jena University Hospital, Jena
3 shared publications - Ulf Teichgräber
Department of Radiology, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany
3 shared publications - Ulrich Beschorner
Univ Heart Ctr Freiburg Bad Krozingen, Bad Krozingen, Germany
3 shared publications - Andrej Schmidt
Division of Angiology, Department of Internal Medicine, Neurology and Dermatology, University Hospital Leipzig, Leipzig, Germany
2 shared publications - Daniela Branzan
Department for Vascular and Endovascular Surgery, TUM University Hospital, Technical University Munich, Munich, Germany
2 shared publications
Latest Publications
- Open Access
- 25 March 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (1) , 167-169
An adipocytokine signature improves diagnostic accuracy for people living with lipoedema
Lipoedema is a chronic adipose tissue disorder often misdiagnosed as obesity due to overlapping symptoms and a lack of biomarkers. In this study, we analysed 13 adipocytokines in 79 women and identified chemerin, FGF21 and adiponectin as key biomarkers for distinguishing lipoedema. Decision tree models achieved up to 95% sensitivity, supporting the potential of these biomarkers for improving diagnostic accuracy, particularly in women with overweight or obesity.
- 25 March 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (1) , 167-169
Open AccessAn adipocytokine signature improves diagnostic accuracy for people living with lipoedema
Lipoedema is a chronic adipose tissue disorder often misdiagnosed as obesity due to overlapping symptoms and a lack of biomarkers. In this study, we analysed 13 adipocytokines in 79 women and identified chemerin, FGF21 and adiponectin as key biomarkers for distinguishing lipoedema. Decision tree models achieved up to 95% sensitivity, supporting the potential of these biomarkers for improving diagnostic accuracy, particularly in women with overweight or obesity.
- 1 July 2022
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 304 (1) , 225-227
Femoropopliteal Drug-coated Balloon Angioplasty: Long-term Results of the Randomized EffPac Trial
Download as PowerPoint
- 1 July 2022
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 304 (1) , 225-227
Femoropopliteal Drug-coated Balloon Angioplasty: Long-term Results of the Randomized EffPac Trial
Download as PowerPoint
- 1 October 2020
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 60 (4) , 636-637
Vessel Calcification Patterns Should Determine Optimal Balloon Size Strategy in Below the Knee Angioplasty Procedures
- 1 October 2020
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 60 (4) , 636-637
Vessel Calcification Patterns Should Determine Optimal Balloon Size Strategy in Below the Knee Angioplasty Procedures
- 1 September 2020
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 296 (3) , 638-640
Two-year Review on Mortality and Morbidity after Femoropopliteal Drug-coated Balloon Angioplasty in the Randomized EffPac Trial
Extended safety review including patients who were lost to follow-up at 2 years revealed no evidence of an increased risk of all-cause mortality after femoropopliteal drug-coated balloon angioplasty.
- 1 September 2020
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 296 (3) , 638-640
Two-year Review on Mortality and Morbidity after Femoropopliteal Drug-coated Balloon Angioplasty in the Randomized EffPac Trial
Extended safety review including patients who were lost to follow-up at 2 years revealed no evidence of an increased risk of all-cause mortality after femoropopliteal drug-coated balloon angioplasty.
- 1 May 2020
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 295 (2) , 478-487
Drug-coated Balloon Angioplasty of Femoropopliteal Lesions Maintained Superior Efficacy over Conventional Balloon: 2-year Results of the Randomized EffPac Trial
Angioplasty of femoropopliteal lesions with the paclitaxel-coated balloon proved to be superior to conventional balloon angioplasty with regard to restenosis and need for repeat revascularization t... Background Paclitaxel drug-coated balloon (DCB) catheter angioplasty is the preferred treatment for revascularization of femoropopliteal lesions in peripheral artery disease, but mortality is a saf...
- 1 May 2020
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 295 (2) , 478-487
Drug-coated Balloon Angioplasty of Femoropopliteal Lesions Maintained Superior Efficacy over Conventional Balloon: 2-year Results of the Randomized EffPac Trial
Angioplasty of femoropopliteal lesions with the paclitaxel-coated balloon proved to be superior to conventional balloon angioplasty with regard to restenosis and need for repeat revascularization t... Background Paclitaxel drug-coated balloon (DCB) catheter angioplasty is the preferred treatment for revascularization of femoropopliteal lesions in peripheral artery disease, but mortality is a saf...
- 1 September 2017
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 90 (6) , 986-993
Analysis of IN.PACT DEEP trial on the association between changes in perfusion from pre‐ to postrevascularization and clinical outcomes in critical limb ischemia
Objectives: To quantify changes in ankle and toe pressure from pre‐ to post‐endovascular revascularization for critical limb ischemia (CLI) and examine their association with major adverse limb events (MALE).Background: Despite societal guidelines recommendation of routine hemodynamic surveillance following revascularization, little is known about hemodynamic assessment in CLI.Methods: Among the 358 patients with CLI from the international multicenter IN.PACT DEEP trial, ankle and toe pressures measurements were available at both baseline and after intervention in 270 and 44 patients, respectively. The change in ankle and toe pressures in response to endovascular revascularization and its association with 1‐year MALE (target limb revascularization, amputation, or death) were examined using Kaplan–Meier curves and multivariable Cox proportional hazard analyses. Corresponding optimal cutoff points were also identified.Results: The mean increase in ankle and toe pressures following revascularization was 33 and 13 mmHg, respectively. Patients with an improvement of ankle pressure >73 mmHg or toe pressure >1 mmHg had similarly the lowest incidence of MALE (23%), while the highest rate of MALE (50%) was found in those whose toe pressure failed to improve by at least 1 mmHg following intervention. In addition, an increase in ankle pressure >73 mmHg was numerically protective against MALE, and more importantly, an increase in toe pressure of >1 mmHg provided statistically significant protection from MALE (adjusted HR = 0.15, 95% CI: 0.04–0.57, P = 0.005).Conclusions: Improvements in toe pressure post revascularization are incremental and rarely normalize. Toe pressure, compared to ankle pressure, is more useful in CLI and predicts future MALE.
- 1 September 2017
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 90 (6) , 986-993
Analysis of IN.PACT DEEP trial on the association between changes in perfusion from pre‐ to postrevascularization and clinical outcomes in critical limb ischemia
Objectives: To quantify changes in ankle and toe pressure from pre‐ to post‐endovascular revascularization for critical limb ischemia (CLI) and examine their association with major adverse limb events (MALE).Background: Despite societal guidelines recommendation of routine hemodynamic surveillance following revascularization, little is known about hemodynamic assessment in CLI.Methods: Among the 358 patients with CLI from the international multicenter IN.PACT DEEP trial, ankle and toe pressures measurements were available at both baseline and after intervention in 270 and 44 patients, respectively. The change in ankle and toe pressures in response to endovascular revascularization and its association with 1‐year MALE (target limb revascularization, amputation, or death) were examined using Kaplan–Meier curves and multivariable Cox proportional hazard analyses. Corresponding optimal cutoff points were also identified.Results: The mean increase in ankle and toe pressures following revascularization was 33 and 13 mmHg, respectively. Patients with an improvement of ankle pressure >73 mmHg or toe pressure >1 mmHg had similarly the lowest incidence of MALE (23%), while the highest rate of MALE (50%) was found in those whose toe pressure failed to improve by at least 1 mmHg following intervention. In addition, an increase in ankle pressure >73 mmHg was numerically protective against MALE, and more importantly, an increase in toe pressure of >1 mmHg provided statistically significant protection from MALE (adjusted HR = 0.15, 95% CI: 0.04–0.57, P = 0.005).Conclusions: Improvements in toe pressure post revascularization are incremental and rarely normalize. Toe pressure, compared to ankle pressure, is more useful in CLI and predicts future MALE.
- 8 May 2011
- Published by SAGE Publications in Angiology
- Vol. 62 (8) , 645-656
The 1-Year Clinical Impact of Rotational Aspiration Atherectomy of Infrainguinal Lesions
The present study was carried out to provide information about outcome of the Jetstream atherectomy device for treatment of infrainguinal arteries. From February 2006 to February 2007, 172 patients with Rutherford class 1 to 5 lower limb ischemia were enrolled at 9 study sites. The endpoints were evaluation of quality of life according to the walking impairment questionnaire (WIQ) besides technical parameters. In the total study cohort, the WIQ scale maintained improved up to 12-month follow-up. Furthermore, target lesion revascularization rate was 26% (42/162), ankle-brachial index (ABI) increased from 0.59 ± 0.21 at baseline to 0.82 ± 0.27 ( P < 0.05), and mean Rutherford class dropped from 3.0 ± 0.9 at baseline to 1.5 ± 1.3 at 1 year ( P < .05). The results of this prospective, multicenter, clinical study demonstrate that the Jetstream atherectomy device is a potential treatment alternative for the endovascular management to improve clinical outcome in patients with peripheral arterial occlusive disease.
- 8 May 2011
- Published by SAGE Publications in Angiology
- Vol. 62 (8) , 645-656
The 1-Year Clinical Impact of Rotational Aspiration Atherectomy of Infrainguinal Lesions
The present study was carried out to provide information about outcome of the Jetstream atherectomy device for treatment of infrainguinal arteries. From February 2006 to February 2007, 172 patients with Rutherford class 1 to 5 lower limb ischemia were enrolled at 9 study sites. The endpoints were evaluation of quality of life according to the walking impairment questionnaire (WIQ) besides technical parameters. In the total study cohort, the WIQ scale maintained improved up to 12-month follow-up. Furthermore, target lesion revascularization rate was 26% (42/162), ankle-brachial index (ABI) increased from 0.59 ± 0.21 at baseline to 0.82 ± 0.27 ( P < 0.05), and mean Rutherford class dropped from 3.0 ± 0.9 at baseline to 1.5 ± 1.3 at 1 year ( P < .05). The results of this prospective, multicenter, clinical study demonstrate that the Jetstream atherectomy device is a potential treatment alternative for the endovascular management to improve clinical outcome in patients with peripheral arterial occlusive disease.